Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the initial purchasers in the offering while Cooley advised Cytokinetics. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, has announced the pricing of its...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the offering. Chinook Therapeutics, Inc. (Nasdaq: KDNY) has announced the pricing of its underwritten public offering of 6,428,572 shares...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised BridgeBio on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has entered into...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the lender, HPS Investment Partners, in the transaction. SDC US SmilePay SPV’s (SPV), a wholly-owned special purpose subsidiary of SmileDirectClub, Inc. announced...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented SLR Investment Corp. in the transaction. Vapotherm, Inc., a global medical technology company focused on the development and commercialization of non-invasive technologies...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Innocoll Biotherapeutics in the transaction. Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Coherus in the transaction. Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed...
You must be a Standard 1 Year member to access this content.
